Vanta Bioscience informs about submission of revised financial statements

19 Sep 2024 Evaluate
In connection with Audited Standalone and Consolidated Financial results for the period ended 31.03.2024 which were approved by the Board in their meeting held on 19.07.2024 and was submitted to BSE on the same date, the Company is in receipt of query from BSE regarding bifurcation of Trade Payables in the statement of assets and liabilities in accordance with Accounting Standard Division 1 Format. Vanta Bioscience has submitted that the Company inadvertently and owing to clerical error, classified all the trade payables into one single head. Accordingly, they are submitting the financials statements of the Company with bifurcation of Trade Payables as per Accounting Standard Division 1 Format. They confirmed that, there are no other changes in the financial statements, audit reports and notes which were previously submitted on 19.07.2024. All the other submissions and disclosures submitted previously on 19.07.2024 remain the same. It has enclosed the revised standalone and consolidated financial results for the period ended 31.03.2024 along with the Auditors Report issued by the statutory auditors of the Company and all other attachments which were submitted on 19.07.2024.

The above information is a part of company’s filings submitted to BSE.

Vanta Bioscience Share Price

50.33 1.35 (2.76%)
28-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 915.70
Sagility India 34.94
AGS Transact Tech 79.93
Just Dial 1119.55
Krystal Integrated 769.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.